

FOR IMMEDIATE RELEASE

CONTACT: Kelly Sladek SCORR Marketing 308.237.5567 Kelly@scorrmarketing.com

Camargo Expands Biologics Service Offering and Appoints Chief Medical Officer

(Cincinnati, OH; January 11, 2011) – <u>Camargo Pharmaceutical Services</u>, a full-service clinical research organization (CRO) specializing in end-to-end drug development through the <u>505(b)(2)</u> process, is pleased to announce the Company's appointment of Ray Dawkins, M.D., as chief medical officer.

Dr. Dawkins brings over 25 years of clinical research and pharmaceutical development experience including Phase I, first-in-human and biologics. Camargo currently provides unique regulatory and program management services for clinical trials and biologics, and plans to add to the Company's résumé with the addition of Dr. Dawkins. He also has expertise in <u>Phase I-III clinical trial</u> <u>design</u>, drug safety reporting, medical writing and international regulatory interaction and submissions.

"The addition of Dr. Dawkins will expand our services to include so-called bio-betters -<u>biologics</u> that are improved over the reference products," stated Ken Phelps, president and CEO of Camargo. "We use our proven knowledge of how to improve small molecule drugs to improve biologic-based drugs. In a sense, we're just living up to our <u>brand</u> and teaching a new dog a new trick."

Prior to joining the Camargo team, Dr. Dawkins was an executive medical director of medical affairs at Paragon Biomedical, located in Cary, North Carolina. He was also the senior medical director of clinical development at Talecris Biotherapeutics, located in Research Triangle Park, North Carolina. In his previous positions, Dr. Dawkins was responsible for planning, implementing, leading and evaluating global projects, as well as business development and product acquisition activities.

Dr. Dawkins received a Doctor of Medicine (M.D.) from Duke University School of Medicine in Durham, North Carolina, and a Bachelor of Science in zoology with high honors from North Carolina State University in Raleigh, North Carolina. He has authored or coauthored numerous publications.

About Camargo Pharmaceutical Services

Camargo Pharmaceutical Services is a full-service CRO for the continuum of drug development. With more than 150 FDA approvals, Camargo works with companies to develop comprehensive programs, managing every facet of the plan from formulation and testing the drug product, conducting clinical studies and FDA application submissions. Connect with Camargo on LinkedIn or visit www.camargopharma.com for more information.